NCT04249648View on ClinicalTrials.gov

Hyperkalaemia and Its Impact on Therapy with RAASi

CompletedOBSERVATIONAL

Enrollment

651

Participants

Timeline

Start Date

July 12, 2021

Primary Completion Date

November 1, 2024

Study Completion Date

November 1, 2024

Conditions

HyperkalaemiaHeart Failure with Reduced Ejection FractionLeft Ventricular Systolic Dysfunction

Trial Locations (1)

Unknown

Portsmouth Hospitals University NHS Trust, Portsmouth

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Vifor Pharma

INDUSTRY

lead

Portsmouth Hospitals NHS Trust

OTHER_GOV

NCT04249648 - Hyperkalaemia and Its Impact on Therapy with RAASi | Biotech Hunter | Biotech Hunter